Other substances

Asunaprevir

A hepatitis C virus protease inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

Asunaprevir is a hepatitis C virus (HCV) NS3 protease inhibitor. It binds to the protease’s catalytic centre and inhibits the viral polyprotein maturation, which leads to inhibition of HCV replication (NCIt).

Asunaprevir on DrugBank
Asunaprevir on PubChem
Asunaprevir on Wikipedia

 

Structure image - Asunaprevir

CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C

Supporting references

Link Tested on Impact factor Notes Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model
Preprint In silico 		in silico Feb/02/2020

AI-suggested references

Link Publication date
Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening
Feb/04/2021
Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation
Apr/20/2021
Export (.csv)